Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

The credit rating agency Moody’s has stripped the United States of its triple-A credit rating, warning investors about rising levels of government debt and a widening budget deficit. The agency has ...

Viking is pushing hard in its development of a weight-loss drug. A major C-suite change at a potential competitor was a key ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

By Patrick Wingrove and Maggie Fick (Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

After nearly tripling the company’s value, CEO Lars Fruergaard Jørgensen is preparing to exit amid boardroom shifts.